Pantothenate kinase-associated neurodegeneration (Hallerworden–Spatze disease): clinical aspects, diagnosis, treatment (literature review and own data)
DOI:
https://doi.org/10.14739/2310-1210.2021.5.222677Keywords:
pantothenate kinase-associated neurodegeneration, brain, Hallervorden–Spatz disease, neurodegeneration with brain iron accumulationAbstract
Aim. To analyze current data of scientific literature on the etiology, pathogenesis, approaches to the diagnosis and treatment of rare orphan disease – pantothenate kinase-associated neurodegeneration and to describe the clinical case of this disease.
Pantothenate kinase-associated neurodegeneration (PKAN) is a rare inherited autosomal recessive disorder caused by mutations in the PANK2 gene, which is located at the chromosomal locus: 20p13-p12.3.
The article presents a literature review and a case report of the diagnosis and treatment of 8-year-old girl with pantothenate kinase-associated neurodegeneration who suffered from progressive motor impairment.
Among the dominant clinical manifestations is a growing extrapyramidal motor disorder, the so-called “dystonic storm”, which can range from severe sensorimotor motor deficits in infants and young children to mild parkinsonism in adults. MRI signs in the form of specific changes in the T2-weighted mode, which detects typical areas of hyperintensive signal in globus pallidus, surrounded by a border of hypointensive signal (“tiger’s eye”) are particular important. Neuroimaging data most likely make possible to suspect a correct diagnosis, reducing the time and cost of additional examinations.
There is no pathogenetic treatment of this disease now. The main directions of currently available symptomatic drug therapy are described. Clinical trials of detoxifying drugs that reduce iron levels in the body (chelation) and surgical treatments are currently underway.
Conclusions. The presented clinical observation once again confirms the complexity of the diagnostic search for orphan diseases of the nervous system. A key place in the diagnosis of pantothenate kinase-associated neurodegeneration belongs to the neuroimaging methods and molecular genetic testing data.
References
Mastrangelo, M. (2019). Clinical approach to neurodegenerative disorders in childhood: an updated overview. Acta Neurologica Belgica, 119(4), 511-521. https://doi.org/10.1007/s13760-019-01160-0
Hogarth, P. (2015). Neurodegeneration with Brain Iron Accumulation: Diagnosis and Management. Journal of Movement Disorders, 8(1), 1-13. https://doi.org/10.14802/jmd.14034
Lehéricy, S., Roze, E., Goizet, C., & Mochel, F. (2020). MRI of neurodegeneration with brain iron accumulation. Current Opinion in Neurology, 33(4), 462-473. https://doi.org/10.1097/WCO.0000000000000844
Bokhari, M., Zulfiqar, H., & Bokhari, S. R. (2021). Hallervorden Spatz Disease. StatPearls. https://www.statpearls.com/ArticleLibrary/viewarticle/22494
Lee, J. H., Park, J., Ryu, H. S., Park, H., Kim, Y. E., Hong, J. Y., Nam, S. O., Sung, Y. H., Lee, S. H., Lee, J. Y., Lee, M. J., Kim, T. H., Lyoo, C. H., Chung, S. J., Koh, S. B., Lee, P. H., Cho, J. W., Park, M. Y., Kim, Y. J., Sohn, Y. H., … Lee, M. S. (2016). Clinical Heterogeneity of Atypical Pantothenate Kinase-Associated Neurodegeneration in Koreans. Journal of Movement Disorders, 9(1), 20-27. https://doi.org/10.14802/jmd.15058
Hogarth, P., Kurian, M. A., Gregory, A., Csányi, B., Zagustin, T., Kmiec, T., Wood, P., Klucken, A., Scalise, N., Sofia, F., Klopstock, T., Zorzi, G., Nardocci, N., & Hayflick, S. J. (2017). Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Molecular Genetics and Metabolism, 120(3), 278-287. https://doi.org/10.1016/j.ymgme.2016.11.004
Razmeh, S., Habibi, A. H., Orooji, M., Alizadeh, E., Moradiankokhdan, K., & Razmeh, B. (2018). Pantothenate kinase-associated neurodegeneration: Clinical aspects, diagnosis and treatments. Neurology International, 10(1), Article 7516. https://doi.org/10.4081/ni.2018.7516
Chang, X., Zhang, J., Jiang, Y., Wang, J., & Wu, Y. (2020). Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration. CNS Neuroscience & Therapeutics, 26(7), 754-761. https://doi.org/10.1111/cns.13294
Akcakaya, N. H., Iseri, S. U., Bilir, B., Battaloglu, E., Tekturk, P., Gultekin, M., Akar, G., Yigiter, R., Hanagasi, H., Alp, R., Cagirici, S., Eraksoy, M., Ozbek, U., & Yapici, Z. (2017). Clinical and genetic features of PKAN patients in a tertiary centre in Turkey. Clinical Neurology and Neurosurgery, 154, 34-42. https://doi.org/10.1016/j.clineuro.2017.01.011
Zeng, J., Xing, W., Liao, W., & Wang, X. (2019). Magnetic resonance imaging, susceptibility weighted imaging and quantitative susceptibility mapping findings of pantothenate kinase-associated neurodegeneration. Journal of Clinical Neuroscience, 59, 20-28. https://doi.org/10.1016/j.jocn.2018.10.090
Alvarez-Cordoba, M., Villanueva-Paz, M., Villalón-García, I., Povea-Cabello, S., Suárez-Rivero, J. M., Talaverón-Rey, M., Abril-Jaramillo, J., Vintimilla-Tosi, A. B., & Sánchez-Alcázar, J. A. (2019). Precision medicine in pantothenate kinase-associated neurodegeneration. Neural Regeneration Research, 14(7), 1177-1185. https://doi.org/10.4103/1673-5374.251203
Klopstock, T., Tricta, F., Neumayr, L., Karin, I., Zorzi, G., Fradette, C., Kmieć, T., Büchner, B., Steele, H. E., Horvath, R., Chinnery, P. F., Basu, A., Küpper, C., Neuhofer, C., Kálmán, B., Dušek, P., Yapici, Z., Wilson, I., Zhao, F., Zibordi, F., … Vichinsky, E. (2019). Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. The Lancet. Neurology, 18(7), 631-642. https://doi.org/10.1016/S1474-4422(19)30142-5
Sharma, L. K., Subramanian, C., Yun, M. K., Frank, M. W., White, S. W., Rock, C. O., Lee, R. E., & Jackowski, S. (2018). A therapeutic approach to pantothenate kinase associated neurodegeneration. Nature Communications, 9(1), Article 4399. https://doi.org/10.1038/s41467-018-06703-2
Kumar, R., Taneja, N., & Gandhi, R. (2018). Anesthetic management of a case of neurodegeneration brain iron accumulation (Hallervorden-Spatz disease). Journal of Anaesthesiology, Clinical Pharmacology, 34(2), 278-279. https://doi.org/10.4103/joacp.JOACP_103_16
De Vloo, P., Lee, D. J., Dallapiazza, R. F., Rohani, M., Fasano, A., Munhoz, R. P., Ibrahim, G. M., Hodaie, M., Lozano, A. M., & Kalia, S. K. (2019). Deep brain stimulation for pantothenate kinase-associated neurodegeneration: A meta-analysis. Movement Disorders, 34(2), 264-273. https://doi.org/10.1002/mds.27563
Tanrıkulu, B., Özen, A., Günal, D. I., Türkdoğan, D., Bayraklı, F., Bayri, Y., Dağçınar, A., & Şeker, A. (2015). Deep brain stimulation as treatment for dystonic storm in pantothenate kinase-associated neurodegeneration syndrome: case report of a patient with homozygous C.628 2 T > G mutation of the PANK2 gene. Acta Neurochirurgica, 157(9), 1513-1517. https://doi.org/10.1007/s00701-015-2514-5
Stetsenko, T. I., & Konoplyanko, T. V. (2013). Khvoroba Hallevordena-Shpattsa. Suchasnyi pohliad na etiolohiiu, patohenez i kliniku u ditei ta doroslykh [Hallervorden-Spatz disease. Modern view on etiology, pathogenesis and clinic in children and adults]. Sovremennaya pediatriya, (3), 147-150. [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)